Q2FY11 preview for Glenmark by Centrum,

Visit http://indiaer.blogspot.com/ for complete details 􀂄 􀂄


Glenmark Pharma (Rating – Buy; Target Price – Rs346)
􀂁 We expect the steady turnaround to continue and the topline to grow by 18% to Rs7bn.
􀂁 The EBIDTA margin is expected to improve by 100bps to 27.5%.
􀂁 We also expect the adjusted PAT to grow by 27.7% on a YoY basis to Rs1bn.